Cempra Inc (NASDAQ:CEMP) was downgraded by research analysts at Vetr from a “buy” rating to a “sell” rating in a report issued on Monday. They currently have a $4.07 price target on the stock. Vetr‘s price target points to a potential downside of 3.10% from the company’s current price.
Several other research firms have also recently issued reports on CEMP. Morgan Stanley raised Cempra from an “underweight” rating to an “equal weight” rating and set a $5.00 price target on the stock in a report on Friday, December 30th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $4.00 price target on shares of Cempra in a report on Wednesday, March 1st. Gabelli cut Cempra from a “buy” rating to a “hold” rating in a report on Wednesday, November 23rd. Zacks Investment Research cut Cempra from a “buy” rating to a “hold” rating in a report on Tuesday, February 28th. Finally, WBB Securities cut Cempra from a “buy” rating to a “hold” rating and dropped their price target for the company from $40.00 to $4.00 in a report on Thursday, December 29th. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $11.88.
Cempra (NASDAQ:CEMP) traded up 9.09% on Monday, reaching $4.20. The company’s stock had a trading volume of 1,974,747 shares. Cempra has a 1-year low of $2.55 and a 1-year high of $26.95. The stock has a 50 day moving average price of $3.42 and a 200-day moving average price of $10.73. The company’s market capitalization is $220.05 million.
Cempra (NASDAQ:CEMP) last posted its quarterly earnings results on Tuesday, February 28th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by $0.03. The company earned $7.95 million during the quarter, compared to the consensus estimate of $4.19 million. Cempra had a negative net margin of 678.72% and a negative return on equity of 59.94%. Cempra’s quarterly revenue was up 37.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.48) EPS. Equities analysts predict that Cempra will post ($1.17) earnings per share for the current fiscal year.
Your IP Address:
In other news, Director Dov A. Md Goldstein sold 937,600 shares of the business’s stock in a transaction on Friday, January 6th. The shares were sold at an average price of $3.41, for a total transaction of $3,197,216.00. Following the transaction, the director now directly owns 95 shares in the company, valued at approximately $323.95. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Dov A. Md Goldstein sold 150,000 shares of the business’s stock in a transaction on Wednesday, March 8th. The shares were sold at an average price of $3.55, for a total transaction of $532,500.00. Following the transaction, the director now owns 95 shares in the company, valued at $337.25. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,193,060 shares of company stock worth $4,088,280. 17.80% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of the stock. Advisor Group Inc. boosted its position in Cempra by 2,258.0% in the third quarter. Advisor Group Inc. now owns 6,508 shares of the company’s stock valued at $157,000 after buying an additional 6,232 shares in the last quarter. SG Americas Securities LLC bought a new position in Cempra during the third quarter valued at approximately $363,000. DORCHESTER WEALTH MANAGEMENT Co bought a new position in Cempra during the third quarter valued at approximately $436,000. M&T Bank Corp bought a new position in Cempra during the third quarter valued at approximately $449,000. Finally, Johnson Investment Counsel Inc. boosted its position in Cempra by 0.5% in the third quarter. Johnson Investment Counsel Inc. now owns 19,690 shares of the company’s stock valued at $476,000 after buying an additional 100 shares in the last quarter. Institutional investors and hedge funds own 79.92% of the company’s stock.
Cempra Company Profile
Cempra, Inc is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections.
To view Vetr’s full report, visit Vetr’s official website.
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2024243/cempra-inc-cemp-stock-rating-lowered-by-vetr-inc.html
Receive News & Ratings for Cempra Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc and related companies with MarketBeat.com's FREE daily email newsletter.